Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Publikation

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Wissenschaftlicher Artikel/Review - 08.08.2016

Jörger Markus, Behringer D M, Ko Y-D, Hilger R A, Roessler M, Kloft C, Henrich A, Moritz B, Miller M C, Salamone S J, Kopp H-G, Mayer F, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Salamone, S J

Jaehde, U